2. Academic Validation
  3. Brain Penetrant LRRK2 Inhibitor

Brain Penetrant LRRK2 Inhibitor

  • ACS Med Chem Lett. 2012 Aug 9;3(8):658-662. doi: 10.1021/ml300123a.
Hwan Geun Choi 1,  Jinwei Zhang,  Xianming Deng,  John M Hatcher,  Matthew P Patricelli,  Zheng Zhao,  Dario R Alessi,  Nathanael S Gray
Affiliations

Affiliation

  • 1 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA ; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 250 Longwood Ave, SGM 628, Boston, MA 02115, USA.
PMID: 23066449 DOI: 10.1021/ml300123a
Abstract

Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson's disease (PD) patients and may represent an attractive therapeutic target. Here we report a 2-anilino-4-methylamino-5-chloropyrimidine, HG-10-102-01(4) is a potent and selective inhibitor of wild-type LRRK2 and the G2019S mutant. Compound 4 substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.1-0.3 µM in cells and is the first compound reported to be capable of inhibiting Ser910 and Ser935 phosphorylation in mouse brain following intraperitoneal delivery of doses as low as 50 mg/kg.

Figures
Products